lenvatinib + tislelizumab + capecitabine + oxaliplatin

This is a combination regimen consisting of four drugs: - **Lenvatinib** is an oral small molecule multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. It inhibits angiogenesis and tumor cell proliferation. - **Tislelizumab** is a humanized IgG4 monoclonal antibody that acts as an immune checkpoint inhibitor by binding to programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 and enhancing antitumor immune responses. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that inhibits thymidylate synthase, leading to impaired DNA synthesis in rapidly dividing tumor cells. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis in cancer cells. This combination brings together targeted therapy (lenvatinib), immunotherapy (tislelizumab), and cytotoxic chemotherapy agents (capecitabine and oxaliplatin). While dual or triple combinations involving these agents have been studied for various solid tumors—most notably hepatocellular carcinoma, biliary tract cancers, and colorectal cancer—the specific quadruple regimen of lenvatinib + tislelizumab + capecitabine + oxaliplatin has not been widely reported in published clinical trials as of May 2025. Each component has demonstrated efficacy within its class; the rationale for combining them would be to maximize antitumor activity through complementary mechanisms.